Schering-Plough Corp. said on Friday its quarterly profit soared on increased sales of the cholesterol medicines it shares with Merck & Co. Inc. and strong demand for its other drugs, sending shares 5.2 percent higher in premarket trading.
WHITEHOUSE STATION, N.J.----Merck & Co., Inc. today announced that EPS for the third quarter of 2006 were $0.51, including the impact of reserving an additional $598 million in the third quarter solely for future VIOXX legal defense costs and excluding a net $0.08 charge for site closures and position eliminations primarily associated with the global restructuring announced in November 2005.
Schering-Plough Corp. on Friday reported higher third-quarter profit on increased sales of the cholesterol medicines it shares with Merck & Co. and solid demand for its allergy and arthritis treatments.
Four drugmakers posted higher quarterly earnings on increased sales of major products on Thursday, with the world's largest drugmaker -- Pfizer Inc. -- heading the charge past Wall Street expectations.
A quartet of drugmakers posted higher quarterly earnings on sales increases of major products on Thursday, with world's largest Pfizer Inc. heading the charge past Wall Street expectations.
Federal regulators approved a new diabetes drug yesterday with two kinds of beneficiaries: millions of people struggling to control their disease, and the drug giant Merck & Co. Inc. laboring to revive its fortunes.
PHILADELPHIA _ Federal regulators approved a new diabetes drug Tuesday with two kinds of beneficiaries: millions of people struggling to control their disease, and the drug giant Merck & Co. Inc. laboring to revive its fortunes.
Merck & Co. Inc. got federal approval today to market a new kind of diabetes drug, the latest aimed at a lucrative but troubling increase in the number of diabetes sufferers.